Fusion Protein To Agonize CD261 And CD262 for Oncology is under clinical development by Beijing Sunbio Biotech and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Fusion Protein To Agonize CD261 And CD262 for Oncology’s likelihood of approval (LoA) and phase transition for Refractory Multiple Myeloma took place on 06 Jan 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 06 Jan 2021 increased Fusion Protein To Agonize CD261 And CD262 for Oncology’s LoA and PTSR for Relapsed Multiple Myeloma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Fusion Protein To Agonize CD261 And CD262 for Oncology Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Fusion Protein To Agonize CD261 And CD262 for Oncology overview

Fusion protein (CPT) is under development for the treatment of relapsed or refractory multiple myeloma. The drug candidate is administered intravenously. It targets TRAIL-R1 (DR4) and TRAIL-R2 (DR5). The drug candidate is a recombinant mutant of human Apo2L/TRAIL. The drug candidate was also under development for brain glioma, breast, lung and colon cancer.

Quick View Fusion Protein To Agonize CD261 And CD262 for Oncology LOA Data

Report Segments
  • Innovator
Drug Name
  • Fusion Protein To Agonize CD261 And CD262 for Oncology
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.